JPS63316729A - Tonic - Google Patents
TonicInfo
- Publication number
- JPS63316729A JPS63316729A JP62154220A JP15422087A JPS63316729A JP S63316729 A JPS63316729 A JP S63316729A JP 62154220 A JP62154220 A JP 62154220A JP 15422087 A JP15422087 A JP 15422087A JP S63316729 A JPS63316729 A JP S63316729A
- Authority
- JP
- Japan
- Prior art keywords
- saponin
- jiaogulan
- water
- gynostemma pentaphyllum
- extracted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001256 tonic effect Effects 0.000 title claims abstract description 13
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 44
- 229930182490 saponin Natural products 0.000 claims abstract description 37
- 150000007949 saponins Chemical class 0.000 claims abstract description 37
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 34
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 16
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 abstract description 9
- 241000196324 Embryophyta Species 0.000 abstract description 5
- 238000010438 heat treatment Methods 0.000 abstract description 5
- 238000007911 parenteral administration Methods 0.000 abstract description 2
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 6
- 239000002198 insoluble material Substances 0.000 abstract 1
- 235000017709 saponins Nutrition 0.000 description 31
- 239000000843 powder Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 230000037396 body weight Effects 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000284 extract Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000027326 copulation Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000009329 sexual behaviour Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical group CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- JXLPOVGRTXYUHF-UHFFFAOYSA-N 3-O-(alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranosyl)serjanic acid 28-O-beta-D-glucopyranoside Natural products C12CC(C(=O)OC)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O JXLPOVGRTXYUHF-UHFFFAOYSA-N 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
本発明はアマチャヅル(G ynostemsa pe
ntaphyllum Makino)に存在するサポ
ニンを有効成分として含有する強壮剤に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention is directed to the Gynostemsa pe
The present invention relates to a tonic containing saponins present in Ntaphyllum Makino as an active ingredient.
本発明者らは、アマチャヅルの生理活性について広範な
研究を行ってきたが、アマチャヅルの水抽出エキスを服
用する人の中に、しばしば精力の増強を訴えるものがあ
り、その原因を究明したところ、それがアマチャヅルの
サポニンに出来することを見い出し、この新知見に基づ
き本発明を完成するに至った。The present inventors have conducted extensive research on the physiological activities of Jiaogulan, and found that some people who take Jiaogulan aqueous extract often complain of increased virility, and upon investigating the cause, found that They discovered that saponin from Jiaogulan can produce this, and based on this new knowledge, they completed the present invention.
すなわち本発明は、アマチャヅルサポニンをを効成分と
して含有する強壮剤を搗供するものである。That is, the present invention provides a tonic containing Jiaogulan saponin as an active ingredient.
アマチャヅルはウリ科に属し、東アジアー帯の山野に自
生する多年性の蔓草である。また、このものは栽培も容
易であり、本発明の強壮剤の原料となる植物の入手は極
めて容易である。本発明の強壮剤の有効成分であるアマ
チャヅルサポニンは、アマチャヅルから例えば次のよう
な方法で得ることができる。アマチャヅルの全草乾燥物
に水を加え、加熱抽出し、抽出液を濃縮乾固して水抽出
エキスとする。この水抽出エキスにメタノールを加え、
加熱抽出し、不溶物を除き、抽出液を層線してメタノー
ル抽出エキスとする。このメタノール抽出エキスを水に
溶解し、それにエーテルを加えてよく振り混ぜたのち下
部の水層を分取し、それに水飽和n−ブタノールを加え
てよく振り混ぜたのち上部のれ一ブタノール層を分取し
、それを濃縮してアマチャヅル粗サポニンとする。次に
このアマチャヅル粗サポニンを出来るだけ少量のメタノ
ールに溶解し、それをエーテルに注ぐとアマチャヅルサ
ポニンが析出する。Jiaogulan belongs to the Cucurbitaceae family and is a perennial vine that grows naturally in the mountains and fields of East Asia. Moreover, this plant is easy to cultivate, and the plant that is the raw material for the tonic of the present invention is extremely easy to obtain. Jiaogulan saponin, which is an active ingredient of the tonic of the present invention, can be obtained from Jiaogulan by the following method, for example. Water is added to the dried whole plant of Jiaogulan, extracted by heating, and the extract is concentrated to dryness to obtain a water extract. Add methanol to this water extract,
Extract by heating, remove insoluble matter, and layer the extract to obtain a methanol extract. Dissolve this methanol extract in water, add ether to it, shake well, separate the lower aqueous layer, add water-saturated n-butanol to it, shake well, and remove the upper one-butanol layer. It is separated and concentrated to produce Jiaogulan crude saponin. Next, this crude Jiaogulan saponin is dissolved in as little methanol as possible and poured into ether to precipitate Jiaogulan saponin.
その具体例を示すと次のとおりである。Specific examples are as follows.
製造例 l
アマチャヅル全草乾燥物250gに10倍量の蒸留水、
すなわち2.5Qの蒸留水を加え、120分間煮沸する
。冷浸、抽出液をろ過し、ろ液を減圧下に6縮乾固し、
赤褐色粉末80gを得た。次にこの赤褐色粉末に10倍
量のメタノール、すなわち800酎のメタノールを加え
、20分間煮沸する。冷浸、抽出液をろ過し、ろ液を減
圧下に濃縮乾固し、褐色粉末309を得た。次にこの褐
色粉末に蒸留水200zQを加え、粉末を完全に溶解さ
せたのちそれを分液漏斗に移し、ついでエーテル200
212を加えてよく振り混ぜたのち下部の水層を分取す
る。この水層については、さらに2回同様の方法でエー
テル抽出を行い、次に水飽和n−ブタノール200x(
7を加えてよく振り混ぜたのち上部のn−ブタノール層
を分取する。下部の水層についてはさらに3回同様の方
法でn−ブタノール抽出を行い、n−ブタノール抽出液
をすべて合わせ、それを減圧下に濃縮乾固し、淡褐色粉
末!2gを得た。Production example l 250g of dried Jiaogulan whole plant, 10 times the amount of distilled water,
That is, add 2.5Q of distilled water and boil for 120 minutes. Cooling, filter the extract, and reduce the filtrate to dryness under reduced pressure for 6 hours.
80 g of reddish brown powder was obtained. Next, 10 times the amount of methanol, that is, 800 liters of methanol, is added to this reddish-brown powder and boiled for 20 minutes. After cooling and filtering the extract, the filtrate was concentrated to dryness under reduced pressure to obtain brown powder 309. Next, add 200 zQ of distilled water to this brown powder, and after completely dissolving the powder, transfer it to a separatory funnel, and then add 200 zQ of distilled water.
After adding 212 and shaking well, separate the lower aqueous layer. This aqueous layer was extracted with ether twice in the same manner, and then water-saturated n-butanol 200x (
After adding 7 and shaking well, separate the upper n-butanol layer. The lower aqueous layer was further extracted with n-butanol in the same manner three times, and all the n-butanol extracts were combined and concentrated to dryness under reduced pressure to form a light brown powder! 2g was obtained.
次にこの淡褐色粉末にメタノール85mCを加え、粉末
を完全に溶解させたのら、それを6Qのエーテルに注ぎ
、析出物をグラスフィルター(G4)でろ過し、黄白色
粉末のアマチャヅルサポニン9゜6gを得た。Next, 85mC of methanol was added to this light brown powder, and once the powder was completely dissolved, it was poured into 6Q ether, the precipitate was filtered through a glass filter (G4), and the yellowish white powder of Jiaogulan saponin 9° 6g was obtained.
上記のようにして得たアマチャヅルサポニンの物性は次
のとおりである。The physical properties of Jiaogulan saponin obtained as described above are as follows.
アマチャヅルサポニンの性状 (+)外観、におい、味 黄白色の粉末で、においはなく、わずかに苦味がある。Properties of Jiaogulan saponin (+) Appearance, smell, taste It is a yellowish white powder, odorless and slightly bitter.
(2)溶解性
水、メタノール、エタノールに可溶、ベンゼン、クロロ
ホルム、エーテル、n−ヘキサン、石油エーテルに不溶
(3)pH
1%水溶液のp)(は6.1である。(2) Solubility Soluble in water, methanol, ethanol, insoluble in benzene, chloroform, ether, n-hexane, petroleum ether (3) pH of 1% aqueous solution is 6.1.
(4)IR(KBr)
3360.1630.1070,1040cJl−’(
5)定性反応
リーベルマン反応、ザルコラスキー反応、バニリン・硫
酸反応は陽性である。また、水晶のO81%水溶液を激
しく振り混ぜるとき、持続性の微細な泡を生じる。(4) IR (KBr) 3360.1630.1070,1040cJl-'(
5) Qualitative reactions Lieberman reaction, Sarcolasky reaction, and vanillin/sulfuric acid reaction are positive. Furthermore, when an 81% O 81% aqueous solution of quartz is vigorously shaken, persistent fine bubbles are produced.
(6)薄層クロマトグラフィー
水晶50R9をメタノール2xQに溶かした液lOμQ
を試料液として、下記の条件で薄層クロマトグラフィー
を行うとき、第1図のごとき薄層クロマトグラムを得る
。(6) Thin layer chromatography A solution of crystal 50R9 dissolved in methanol 2xQ 1OμQ
When performing thin layer chromatography under the following conditions using as a sample solution, a thin layer chromatogram as shown in FIG. 1 is obtained.
プレート:キーゼルゲル60F254(メルク社製)
展開溶剤:クロロホルム−メタノール−水混液(65:
35:10)の下層
展開距離+IOc*
検 出:1%硫酸第二セリウム−10%硫酸溶液を噴
霧した後105℃で5分間加熱
する。Plate: Kieselgel 60F254 (Merck) Developing solvent: Chloroform-methanol-water mixture (65:
Detection: 1% ceric sulfate-10% sulfuric acid solution is sprayed and then heated at 105° C. for 5 minutes.
(7)高速液体クロマトグラフィ一
本島75肩9をメタノール2j112に溶かした液10
μgを試料液として、下記の条件で高速液体クロマトグ
ラフィーを行うとき、第2図のごとき高速液体クロマト
グラムを得る。(7) High performance liquid chromatography Solution 10 in which main island 75 shoulder 9 was dissolved in methanol 2j112
When high performance liquid chromatography is performed using μg as a sample liquid under the following conditions, a high performance liquid chromatogram as shown in FIG. 2 is obtained.
装 置:高滓高速液体クロマトグラフL(、−6A(シ
ステムコントローラ5CL−A付)カラム:L 1ch
rosorb RP −18(メルク社製)内径4 m
m、長さ25cxのステンレスカラム
カラム温度=30℃
移動層:水−アセトニトリル混液(65・35)流 速
:0分(0,5xL/分)−15分(0,5a+ff/
分)=30分(1,0x12/分)→45分(2,4W
!/分)検出器:紫外分光光度計5PD−6A(高滓)
測定波長202nm
感 度0.16Aufs
データ処理装置:クロマトパックC−43A(島11t
)チャートスビー15mm/分
次に、アマチャヅルサポニンが強壮作用を有することに
ついて実験例を挙げて説明する。Equipment: High performance liquid chromatograph L (-6A (with system controller 5CL-A) Column: L 1ch
rosorb RP-18 (manufactured by Merck & Co.) Inner diameter 4 m
m, length 25cx stainless steel column Column temperature = 30°C Mobile phase: Water-acetonitrile mixture (65.35) Flow rate: 0 min (0.5xL/min) - 15 min (0.5a+ff/
minutes) = 30 minutes (1,0x12/minute) → 45 minutes (2,4W
! /min) Detector: Ultraviolet spectrophotometer 5PD-6A (Takashi)
Measurement wavelength 202nm Sensitivity 0.16Aufs Data processing device: Chromatopack C-43A (Island 11t
) Chart bee 15 mm/min Next, the tonic effect of Jiaogulan saponin will be explained using experimental examples.
実験例!
試験に用いた動物はICR系の雌雄マウスで、10週迎
合経過した時点で試験に供した。性行動の観察は、1日
1回、10匹の雌マウスと1匹の雄マウスを10分間同
居させ、モニターテレビを通じてその交尾回数を測定し
た。なお、雌マウスを常時発情の状態にするため、実験
開始4日前から実験終了まで毎日1回エストラジオール
ベンゾエートを体重にg当たり10μ9皮下注射し、さ
らに実験開始2日前に1回プロゲステロンを体重にg当
たりlx9皮下注射した。雄マウスは、はじめの8日間
は無処理のまま、前記のホルモン剤を投与した雌マウス
と1日1回同居させて交尾回数を測定し、1回10分間
の同居で、8日間交尾が全く認められなかった雄マウス
を選び、それを1群8匹として、対照群と試験群Aおよ
びBの3群を用意し、以後対照群には水1日1回10x
I2/に9体重を、試験群Aには製造例1の水抽出操作
で得た赤褐色粉末の8%水溶液を1日1回10mC/に
9体重(アマチャヅルサポニンとしてl OOx9/
kg体重)の割合で、試験群Bには製造例1で得たアマ
チャヅルサポニンの1%水溶液を1日1回10xff/
に9体重(アマチャヅルサポニンとして100 x9/
kg体重)の割合で経口投与し、いずれも投与前と同
じ方法で8日間性行動の観察を続けた。なお、実験成績
の統計処理には、S tudent’ −を検定または
χ”検定を用いた。その結果、表1に示すごとく、被験
物質投与期間中の試験群Aおよび試験群Bの交尾回数及
び延交尾動物数は対照群に比べ有意に増加し、被験物質
である製造例1の赤褐色粉末及びアマチャヅルサポニン
に強力な強壮作用が認められた。なお、試験群Aに投与
した赤褐色粉末については、さきに本発明者らが考案し
たアマチャヅルサポニンの定量方法(公開特許公報 昭
6O−219566)により、そのアマチャヅルサポニ
ンの含有量を定量し、この定量結果に基づき、投与群B
には投与群Aに投与した赤褐色粉末中に含まれるアマチ
ャヅルサポニンと同量のアマチャヅルサポニンを投与し
たが、両群の交尾回数及び延交尾動物数に有意差が認め
られないことから、赤褐色粉末の強壮作用はもっばらア
マチャヅルサポニンによるものであることが明らかとな
った。Experimental example! The animals used in the test were male and female ICR mice, and they were used for the test after 10 weeks of compliance. To observe sexual behavior, 10 female mice and 1 male mouse were allowed to live together for 10 minutes once a day, and the number of copulations was measured using a monitor TV. In order to keep female mice in constant estrus, estradiol benzoate was subcutaneously injected at 10μ9 per gram of body weight once a day from 4 days before the start of the experiment until the end of the experiment, and progesterone was injected once per gram of body weight 2 days before the start of the experiment. Ix9 was injected subcutaneously. Male mice were left untreated for the first 8 days, and the number of copulations was measured by allowing them to cohabit with female mice administered with the hormone once a day. Select male mice that were not recognized and prepare 3 groups of 8 mice per group: a control group and test groups A and B. From then on, the control group received 10x water once a day.
For test group A, an 8% aqueous solution of the reddish brown powder obtained by the water extraction procedure of Production Example 1 was added once a day to 10 mC/9 body weight (1 OOx9/ as Jiaogulan saponin).
kg body weight), test group B received 1% aqueous solution of Jiaogulan saponin obtained in Production Example 1 at a rate of 10 x ff/kg body weight once a day.
9 body weight (100 x 9/ as Jiaogulan saponin)
kg body weight), and sexual behavior was observed for 8 days in the same manner as before administration. In addition, the Student' - test or the χ" test was used for statistical processing of the experimental results. As a result, as shown in Table 1, the number of copulations in test group A and test group B during the test substance administration period and The number of mated animals increased significantly compared to the control group, and the test substances, the reddish-brown powder of Production Example 1 and Jiaogulan saponin, were found to have a strong tonic effect.The reddish-brown powder administered to test group A was found to have a strong tonic effect. First, the content of Jiaogulan saponin was determined by the method for quantifying Jiaogulan saponin devised by the present inventors (Public Patent Publication No. 6O-219566), and based on this quantitative result, administration group B was determined.
The same amount of Jiaogulan saponin was administered as that contained in the reddish-brown powder administered to administration group A, but there was no significant difference in the number of copulations or the total number of mated animals between the two groups. It became clear that the tonic effect was mainly due to Jiaogulan saponin.
次に、アマチャヅルサポニンの毒性について説明する。Next, the toxicity of Jiaogulan saponin will be explained.
実験例2
試験に用いた動物はICR系の雄マウスで、1群につき
8匹を使用した。4迎合、体重18〜229のものを購
入し、恒温恒湿(23±i℃、55±5%)の飼育室で
固型飼料(MP、オリエンタル酵母工業製)および水を
自由に与えて1週間予備飼育し、その中で成育良好なも
のを選んで試験に供した。試験動物はあらかじめ16時
間絶食させたのち、被験物質を経口投与または腹腔内注
射した。被験物質は、経口投与の場合は水に溶かし、2
0 zQ/ kg体重、腹腔内注射の場合は生理食塩水
に溶かし、10*(2/ky体重の投与液量で投与した
。Experimental Example 2 The animals used in the test were ICR male mice, 8 mice per group. 4, weighing 18 to 229, and feeding them solid feed (MP, manufactured by Oriental Yeast Industry) and water ad libitum in a constant temperature and humidity room (23 ± i ° C, 55 ± 5%). They were preliminarily bred for a week, and those with good growth were selected for testing. After the test animals had been fasted for 16 hours, the test substance was orally administered or intraperitoneally injected. For oral administration, the test substance should be dissolved in water and
In the case of intraperitoneal injection, it was dissolved in physiological saline and administered at a dose of 10*(2/ky body weight).
投与168時間後の死亡率から50%致死量をフクンデ
ルベルデン(Van der Waerden)法[伴
義雄・医薬品研究法、101−102頁、朝倉書店(1
970)]により算出した。その結果、アマチャヅルサ
ポニンの50%致死量は、マウス腹腔内投与で712所
/に9体重(95%信頼限界655〜775H/に9体
重)であった。経口投与の場合は4000 H/ kg
体重の投与で死亡例は認められず、LD!。の測定は不
可能であった。Based on the mortality rate 168 hours after administration, the 50% lethal dose was calculated using the Van der Waerden method [Yoshio Ban, Pharmaceutical Research Methods, pp. 101-102, Asakura Shoten (1)
970)]. As a result, the 50% lethal dose of Jiaogulan saponin was 9 body weight at 712 sites/9 body weight (95% confidence limit: 655 to 775 H/9 body weight) when administered intraperitoneally to mice. 4000 H/kg for oral administration
No deaths were observed with administration of body weight, and LD! . measurement was not possible.
以上の毒性試験から明らかなように、アマチャヅルサポ
ニンの毒性は極めて低く、医薬品としての利用に充分堪
え得るものである。As is clear from the above toxicity tests, the toxicity of Jiaogulan saponin is extremely low and can be used as a pharmaceutical.
アマチャヅルサポニンの強壮作用についての実検データ
および急性毒性試験の結果から考えて、本発明に係るア
マチャヅルサポニンの投与量は、先考の年令、性別、体
重、症状等によって変動するか、経口投与の場合、体重
1kg当たり1日に1〜500*g、好ましくは10−
100所、非経口投与の場合、体重1kg当たり1日に
0.25〜125屑9、好ましくは2.5〜25xgの
範囲が有利である。なお投与は1日量を数回に分けて投
与するのが好ましい。なお、症状によっては、この上限
の薬用量を越えて投与することもできる。Considering the practical data and the results of acute toxicity tests regarding the tonic effect of Jiaogulan saponin, the dosage of Jiaogulan saponin according to the present invention may vary depending on the age, sex, weight, symptoms, etc., or it can be administered orally. 1 to 500*g per kg of body weight per day, preferably 10-
For parenteral administration, a range of 0.25 to 125 g, preferably 2.5 to 25 x g per kg of body weight per day is advantageous. In addition, it is preferable to administer the daily dose in several doses. In addition, depending on the symptoms, it is also possible to administer doses exceeding this upper limit.
アマチャヅルサポニンはそのままでも強壮剤として使用
することができるが、これに通常の製剤に用いられる賦
形剤、補助剤などを加えて製剤製法の常法に従って散剤
、顆粒剤、錠剤、カプセル剤、注射剤などの製剤にして
用いることができる。Jiaogulan saponin can be used as a tonic as it is, but by adding excipients, adjuvants, etc. used in normal preparations, it can be prepared into powders, granules, tablets, capsules, and injections according to the usual method of preparation. It can be used in preparations such as drugs.
次に製剤例を示して本発明を具体的に説明するが、本発
明はこれにより制限されるものではない。Next, the present invention will be specifically explained with reference to formulation examples, but the present invention is not limited thereto.
製剤例1 散剤
5重量部の、製造例1で得たアマチャヅルサポニンを9
5部のラクトースと均等に混和し、散剤とする。Formulation Example 1 9 parts of Jiaogulan saponin obtained in Production Example 1 were added to 5 parts by weight of the powder.
Mix evenly with 5 parts of lactose to form a powder.
製剤例2 顆粒剤
5重量部の、製造例1で得たアマチャヅルサポニンを9
3部のラクトースと混合し、2部のヒドロキシプロピル
セルロースを結合剤として用いて常法に従って顆粒とす
る。Formulation Example 2 Granules 5 parts by weight of Jiaogulan saponin obtained in Production Example 1 were added to 9
Mix with 3 parts of lactose and granulate using 2 parts of hydroxypropylcellulose as binder in a conventional manner.
製剤例3 錠剤
5重量部の、製造例!で得たアマチャヅルサポニンを9
1部のラクトースと混合し、2部のヒドロキシプロピル
セルロースを結合剤として用いて常法に従って顆粒とし
た後、1部のタルクおよび1部のステアリン酸マグネシ
ウムを加え、圧縮成型して錠剤を得る。Formulation Example 3 Manufacturing example of 5 parts by weight of tablets! 9 Jiaogulan saponins obtained from
After mixing with 1 part of lactose and granulating in a conventional manner using 2 parts of hydroxypropylcellulose as a binder, 1 part of talc and 1 part of magnesium stearate are added and compression molded to obtain tablets.
製剤例4 カプセル
5重量部の、製造例!で得たアマチャヅルサポニンを9
3部のラクトースと混合し、2部のヒドロキシプロピル
セルロースを結合剤として用いて常法に従って顆粒とし
、ハードゼラチンカプセルに充填する。Formulation Example 4 Production example of 5 parts by weight of capsules! 9 Jiaogulan saponins obtained from
Mix with 3 parts of lactose, granulate using 2 parts of hydroxypropyl cellulose as a binder in a conventional manner and fill into hard gelatin capsules.
製剤例5 注射剤
1重量部の、製造例1で得たアマチャヅルサポニンを9
9部の生理食塩水に加温溶解した後、滅菌して注射剤と
する。Formulation Example 5 Injection 1 part by weight of Jiaogulan saponin obtained in Production Example 1 was added to 9
After heating and dissolving in 9 parts of physiological saline, the solution is sterilized to prepare an injection.
第1図は本発明に係るアマチャヅルサポニンの薄層クロ
マトグラムを示すグラフである。
図中、・は濃紅紫色、Oは紅紫色、(:′、・は浅紅紫
色のスポットを表す。
第2図は本発明に係るアマチャヅルサポニンの高速液体
クロマトグラムを示すグラフである。FIG. 1 is a graph showing a thin layer chromatogram of Jiaogulan saponin according to the present invention. In the figure, * represents a dark red-purple spot, O represents a red-purple spot, and (:', * represent a light red-purple spot. FIG. 2 is a graph showing a high-performance liquid chromatogram of Jiaogulan saponin according to the present invention.
Claims (1)
らなる強壮剤A tonic containing Jiaogulan saponin as an active ingredient
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62154220A JPS63316729A (en) | 1987-06-19 | 1987-06-19 | Tonic |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62154220A JPS63316729A (en) | 1987-06-19 | 1987-06-19 | Tonic |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS63316729A true JPS63316729A (en) | 1988-12-26 |
Family
ID=15579471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62154220A Pending JPS63316729A (en) | 1987-06-19 | 1987-06-19 | Tonic |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS63316729A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007065539A1 (en) * | 2005-12-06 | 2007-06-14 | Unilever Plc | Extracts of gynostemma and compositions for reducing blood lipid levels |
-
1987
- 1987-06-19 JP JP62154220A patent/JPS63316729A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007065539A1 (en) * | 2005-12-06 | 2007-06-14 | Unilever Plc | Extracts of gynostemma and compositions for reducing blood lipid levels |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5589182A (en) | Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression | |
CN111494507B (en) | Preparation method of internal heat clearing tablets | |
JPS63316729A (en) | Tonic | |
Kim et al. | Isolation of N-methylmorpholine from the seeds of Cassia occidentalis (coffee senna) | |
RU2000120474A (en) | PHARMACEUTICAL COMPOSITION POSSESSING ANTITUM ACTIVITY AND METHOD FOR PRODUCING IT | |
KR102085774B1 (en) | Pharmaceutical composition for prevention or treatment of colon cancer | |
CN109200103A (en) | The preparation method of daphniphyllum calycinum and Herba polygoni hydropiperis extract | |
KR101989739B1 (en) | Composition for preventing or treating diabetes mellitus comprising Rorippa globosa extracts | |
JPS5859921A (en) | Carcinostatic agent containing amachazuru saponin | |
CN105796692A (en) | Waist-strengthening and kidney-invigorating tablet and preparation method thereof | |
JPH05139982A (en) | Ischemic encephalopathy improving agent | |
JPH09208480A (en) | Substance p-antagonizing medicine | |
JPH0930983A (en) | Apoptosis inhibitor | |
DE2311552A1 (en) | PREPARATIONS CONTAINING EXTRACTS OF PLANTS OF THE GENUS AVENA IN TABLETS OR GRANULAR FORM | |
US3832343A (en) | Process for obtaining an extract of arnica montana | |
US20040146468A1 (en) | Oral compositon comprising an extract from the bark of albizzia myrioplylla | |
KR102421081B1 (en) | A composition for anti-smoke comprising niacin | |
CN114436887B (en) | New alkaloid in traditional Chinese medicine coix seeds and extraction and purification method and application thereof | |
JPS627172B2 (en) | ||
JPS5852273A (en) | Aconitine-alkaloid, its preparation, and antiphlogistic anodyne containing it | |
WO2001039785A1 (en) | Formulation containing peanut leaf extract and its preparation | |
JPS632928A (en) | Analgesic | |
KR960015140B1 (en) | The process for the preparation of tablet woo-hwang-chong-sim-won | |
JPS63202357A (en) | Health food | |
CN112569268A (en) | A composition for treating respiratory system diseases and its preparation method |